Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Baricitinib in Systemic Sclerosis
NCT05300932Phase 4Active, not recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2022
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of baricitinib in systemic sclerosis (SSc) (2 arms), sponsored by Tongji Hospital. Primary endpoint: modified Rodnan skin score at 24 weeks. Started Mar 2022; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05300932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300932.